Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M

Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders. The post Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M…

Read More

Software Living in an Enterprise World: Why Digital Behavioral Health Can’t Gain Traction

By TREVOR VAN MIERLO Let’s face it: for the past 25 years, digital behavioral health has struggled. Yet, we keep reinventing (and funding) the same models over and over again. How It All Started In the beginning (mid-1990s), a handful of developers, researchers, and investors envisioned high reach, lower-cost, highly tailored, anonymous interventions reaching millions…

Read More

Links

FDA: Fast-review vouchers to be tied to lower US pricesWhy FDA rejects drugs (in their own words)Kaiser Health News on prior authorizations.Measles: 1,288 cases in the US this yearImpact of ChatGPT on language.

Read More